Merck’s new crown oral drug is approved by the UK regulatory agency
According to reports, the British Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the new crown oral drug molnupiravir developed by Merck (MRK.US) and Ridgeback Biotherapeutics. According to a statement from Merck and Ridgeback, MHRA has approved its new crown oral drug molnupiravir for the treatment of patients with mild to moderate new crowns.
It is reported that in a previous interim analysis of a phase 3 clinical trial involving patients with mild to moderate new crowns, Merck’s drug molnupiravir can reduce the risk of hospitalization or death by about 50%.
As of press time, Merck & Co. rose 1.67% before the market to $90.16.